Clinical Trial Update: Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating paclitaxel and carboplatin plus galunisertib in patients with uterine or ovarian carcinosarcoma has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Carcinosarcoma
• Uterine Carcinosarcoma

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Galunisertib (galunisertib)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: University of Oklahoma | Conditions: Carcinosarcoma, Ovarian | Phase 1 | Status: COMPLETED | Results posted: 2024-08-07